2015-2017 ACBS Child Combined Prevalence Tables
Table 8
Estimated percent using inhaled short acting beta agonists among children 1 with current 2 asthma status by state/territory – BRFSS Asthma Call-back Survey, United States, 2015-2017.
| State/Territory | Current | |||
|---|---|---|---|---|
| Sample size± |
% | SE§ | 95% CI† | |
| California | 101 | 50.1 | 6.2 | (37.9 – 62.3) |
| Connecticut | 152 | 58.4 | 5.0 | (48.6 – 68.2) |
| Florida | 229 | 26.9 | 5.0 | (17.1 – 36.7) |
| Georgia | 100 | 33.6 | 6.1 | (21.6 – 45.6) |
| Hawaii | 82 | 32.0 | 7.2 | (17.9 – 46.1) |
| Indiana | 124 | 46.4 | 6.7 | (33.3 – 59.5) |
| Kansas | 245 | 55.9 | 3.8 | (48.5 – 63.3) |
| Maine | 132 | 48.0 | 7.3 | (33.7 – 62.3) |
| Michigan | 192 | 48.3 | 4.4 | (39.7 – 56.9) |
| Minnesota | 228 | 41.4 | 4.2 | (33.2 – 49.6) |
| Missouri | 68 | 46.7 | 7.2 | (32.6 – 60.8) |
| Montana | 72 | 59.1 | 8.8 | (41.9 – 76.3) |
| Nebraska | 197 | 47.8 | 5.6 | (36.8 – 58.8) |
| New Jersey | 202 | 32.4 | 4.8 | (23.0 – 41.8) |
| New Mexico | 105 | 48.9 | 6.9 | (35.4 – 62.4) |
| New York | 95 | 37.1 | 7.1 | (23.2 – 51.0) |
| Ohio | 157 | 43.8 | 6.4 | (31.3 – 56.3) |
| Oregon | 68 | 67.7 | 7.1 | (53.8 – 81.6) |
| Pennsylvania | 85 | 52.1 | 7.5 | (37.4 – 66.8) |
| Rhode Island | 69 | 54.0 | 7.6 | (39.1 – 68.9) |
| Utah | 191 | 51.7 | 4.6 | (42.7 – 60.7) |
| Vermont | 81 | 50.1 | 7.1 | (36.2 – 64.0) |
| Wisconsin | 42 | 65.7 | 9.5 | (47.1 – 84.3) |
| Puerto Rico | 143 | 15.8 | 4.1 | (7.8 – 23.8) |
| 24 States / Area | 3,160 | 43.1 | 1.8 | (39.6 – 46.6) |
| Median | 48.2 | |||
| Range | 15.8-67.7 | |||
1 Aged < 18 years
2 “Yes” response to “Do you still have asthma?”
± Sample size is for multiple years of participation. Responses of “Don’t Know” and “Refused” are excluded.
§ Standard error
† Confidence interval
Link for Summary Data Quality Report: https://www.cdc.gov/brfss/acbs/2017/pdf/sdq_report_acbs_17-508.pdfpdf iconpdf icon
Page last reviewed: February 16, 2021